D e s i g n
Randomized (allocation concealed*), unblinded,* controlled trial with mean 4.8-year follow-up (Antihypertensive and LipidLowering Treatment to Prevent Heart Attack Trial [ALLHAT-LLT]).
S e t t i n g
513 clinical centers in the United States, Canada, Puerto Rico, and the U.S. Virgin Islands.
P a t i e n t s 10 355 patients (mean age 66 y, 51% men) who were enrolled in the ALLHAT (age ≥ 55 y and stage 1 or 2 hypertension with ≥ 1 additional risk factor for CHD; fasting LDL-C level 3.1 to 4.9 mmol/L for those with no known CHD, or 2.6 to 3.3 mmol/L for those with known CHD; and fasting triglyceride levels < 3.9 mmol/L). Patients were excluded if they were receiving lipid-lowering therapy, large doses of niacin, or probucol; were intolerant of statins; or had liver or kidney disease, other contraindications for statin therapy, or a known secondary cause of hyperlipidemia. Follow-up was 97%. All randomized patients were included in the analysis.
I n t e r v e n t i o n
Patients were allocated to open-label pravastatin, 40 mg/d (n = 5170), or usual care (LDL-C lowering at the discretion of the primary care physician) (n = 5185).
M a i n o u t c o m e m e a s u r e s
All-cause mortality. Secondary outcomes included a composite of fatal CHD or nonfatal myocardial infarction (MI) (CHD events), cause-specific mortality, and total and site-specific cases of cancer.
M a i n r e s u l t s
Analysis was by intention to treat. Pravastatin and usual-care groups did not differ for allcause mortality (Table) . Groups also did not differ for CHD events (Table) or for any other secondary outcomes.
C o n c l u s i o n
In older patients with well-controlled hypertension and moderately elevated low-density lipoprotein cholesterol, pravastatin was no better than usual care in reducing all-cause mortality and CHD events. 
C o m m e n t a r y
Unlike the ALLHAT hypertension treatment trial, in which negative results justified a firm endorsement of a drug of first choice, the negative results of the companion ALLHAT lipid-lowering trial (ALLHAT-LLT) are unimportant.
The negative results probably reflect flaws in study design and thus do not challenge beliefs about statins, especially in light of the positive results from the larger and more rigorous Heart Protection Study (HPS) (1) . The design flaw that sets it apart from the 9 other large, long-term statin trials-including HPS-is the open-label, unblinded design that allowed nearly 30% of the control group to "drop-in" on lipid-lowering therapy. By year 6, the absolute difference in the reduction in LDL-C between the intervention group (28%) and control group (16%) was only 12%.
At the start of ALLHAT-LLT in 1994, the value of statins for primary prevention among patients with only moderately elevated cholesterol and other cardiovascular risk factors was uncertain. Subsequent publication of several positive, blinded, placebo-controlled, randomized trials provided convincing supporting evidence. Thus, only a meticulously designed, large, negative trial with minimal crossover could have challenged this conclusion. We agree with the authors' concluding advice to ignore the results and continue prescribing statins for patients with elevated risk for cardiovascular disease.
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